ClinicalTrials.gg
Active, not recruitingNCT06112379Updated Oct 21, 2026

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

A Phase 3 interventional study of Dato-DXd and Durvalumab in Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 283 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,902
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing datopotamab deruxtecan in Breast Neoplasms — 8 open to participants now, 14 under way, 6 of them phase 3. datopotamab deruxtecan · Breast Neoplasms.

Enrollment
2nd of 14
1,902 · median 300
Started
2023
with 2 others
Phase 3
6 of 14
2 open now
Primary completion
2028-11
later than 11 of 13 live
Registered
7th of 14
by date
Lead sponsor
7 of 14
AstraZeneca

Among the 14 studies testing datopotamab deruxtecan in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 6 in phase 3, reaches primary completion later than 11 of the 13 other live ones, and was the 7th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing datopotamab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing datopotamab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

Read the detailed description

The primary objectives of the study are to demonstrate superiority of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy relative to neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer, by investigator assessment of EFS.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer;
  • Dato-DXd; DS1062a;
  • TROP2;
  • TNBC;
  • HR low:
  • Datopotamab deruxtecan;
  • Antibody Drug Conjugate;
  • ADC;
  • neoadjuvant therapy;
  • adjuvant therapy;
  • durvalumab;
  • PD-L1;
  • immune-checkpoint inhibitor (ICI);
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years, at the time of signing the ICF.
  • confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/-negative breast cancer
  • PS of 0 or 1
  • Provision of acceptable tumor sample
  • Adequate bone marrow reserve and organ function
  • use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and aligned with protocol requirements.

Exclusion criteria

Exclusion criteria:

  • History of any prior invasive breast
  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 5 years before randomization.
  • active or prior documented or inflammatory disorders.
  • Evidence of distant disease.
  • corneal disease.
  • Has active or uncontrolled or C virus infection.
  • Known infection that is not well controlled.
  • Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections.
  • Known to have active tuberculosis infection
  • Mean resting corrected interval > 470 ms obtained from
  • Uncontrolled or significant cardiac disease.
  • History of non-infectious ILD/pneumonitis
  • Has severe pulmonary function compromise
  • Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/-negative breast cancer
  • For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant.
  • Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer.
  • Concurrent use of systemic hormone replacement therapy or oral hormonal
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,902 participants (actual)

Study arms

  • Experimental
    Dato-DXd plus durvalumab

    Participants receive durvalumab every 3 weeks (Q3W) + Dato-DXd Q3W as neoadjuvant therapy prior to surgery; followed by 9 cycles of durvaluamb Q3W as adjuvant therapy post-surgery. Adjuvant chemotherapy may be given in combination with durvalumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease Adjuvant chemotherapy may be one of these: 1. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) and carboplatin (weekly or Q3W) for 4 cycles (12 weeks); 2. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) for 4 cycles (12 weeks); 3. Carboplatin (weekly or Q3W) + paclitaxel (weekly) for 4 cycles (12 weeks); 4. Capecitabine (Q3W) for 8 cycles.

    Drug: Dato-DXd · Drug: Durvalumab · Drug: Doxorubicin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Paclitaxel · Drug: Carboplatin · Drug: Capecitabine · Drug: Olaparib

  • Active comparator
    Pembrolizumab plus chemotherapy

    Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Adjuvant capecitabine (Q3W) for 8 cycles may be given in combination with pembrolizumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease.

    Drug: Pembrolizumab · Drug: Doxorubicin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Paclitaxel · Drug: Carboplatin · Drug: Capecitabine · Drug: Olaparib

Interventions

  • Experimental drug IV infusion

    Also known as: Datopotamab deruxtecan (Dato-DXd, DS-1062a)

  • Experimental drug IV Infusion

    Also known as: MEDI4736

  • IV Infusion Active comparator

    Also known as: KEYTRUDA®

  • IV infusion Experimental/Active Comparator

  • IV Infusion Experimental/Active Comparator

  • IV infusion Experimental/Active Comparator

  • IV infusion Experimental/Active Comparator

  • IV infusion Experimental/Active Comparator

  • Tablet Oral route of administration Experimental/Active Comparator

    Also known as: XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord

  • Tablet Oral route of administration Experimental/Active Comparator

    Also known as: LYNPARZA®

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS) in the experimental vs control arms

    EFS is defined as the time from the date of randomisation until the date of the first occurrence of any of the following events: disease progression precluding surgery, disease recurrence (local, regional, distant, or contralateral), second primary invasive cancer (other than squamous or basal cell skin cancer), or relapse from prior malignancy, or death by any cause (in the absence of recurrence). Non-invasive breast cancers and positive margins in the surgical sample do not count as an event for EFS. EFS will be determined by the investigator based on all available clinical assessments. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest will be the Hazard Ratio of EFS.

    Time frame: Date of randomization to date of the EFS event, up to 93 months after the first subject randomized

Secondary outcomes

  1. Pathologic Complete Response (pCR) in the experimental vs control arms

    pCR rate is defined as the proportion of participants who have no evidence by haematoxylin and eosin staining of residual invasive disease or lymphovascular invasion at the time of definitive surgery in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by blinded central evaluation. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest will be the difference between the pCR rates.

    Time frame: At the time of definitive surgery

  2. Overall Survival (OS) in the experimental vs control arms

    Key Secondary - OS is defined as the time from the date of randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest will be the Hazard Ratio of OS.

    Time frame: Date of randomization to date of death due to any cause, up to 108 months after the first subject randomized

  3. Distant disease-free survival (DDFS) in the experimental vs control arms

    DDFS is defined as the time from the date of randomisation until the date of the first occurrence of any of the following events: distant metastasis, occurrence of second primary invasive cancer (other than squamous or basal cell skin cancer), relapse from prior malignancy or death by any cause (in the absence of recurrence). DDFS will be determined by the investigator based on all available clinical assessments. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest will be the Hazard Ratio of DDFS.

    Time frame: Date of randomization to date of the DDFS event, up to 93 months after the first subject randomized

  4. Participant-reported breast and arm symptoms in the experimental vs. control arms

    Breast and arm symptoms measured by the EORTC IL116. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest is the mean between-arm difference in breast and arm symptom scores.

    Time frame: From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first.

  5. Participant-reported physical function in the experimental vs. control arms

    Physical function measured by the PROMIS Physical Function Short Form 8c. The analysis will include all dosed participants. The measure of interest is the mean between-arm difference in physical function scores.

    Time frame: From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).

  6. Participant-reported fatigue in the experimental vs. control arms

    Fatigue measured by the PROMIS Fatigue Short Form 7a. The analysis will include all dosed participants. The measure of interest will be the difference on the proportions of participants reporting different levels of fatigue and mean between-arm difference in the fatigue scores.

    Time frame: From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).

  7. Participant-reported Global health status/Quality of life (GHS/QoL)in the experimental vs. control arms

    Global health status/Quality of life measured by EORTC IL172. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest is the mean between-arm difference in GHS/QoL scores.

    Time frame: From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).

  8. Pharmacokinetics of Dato-DXd (in combination with durvalumab)

    Plasma concentrations of Dato-DXd (ug/ml )

    Time frame: Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

  9. Pharmacokinetics of Dato-DXd (in combination with durvalumab)

    Plasma concentrations of total anti-TROP2 antibody (ug/ml )

    Time frame: Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

  10. Pharmacokinetics of Dato-DXd (in combination with durvalumab)

    Plasma concentrations of DXd (MAAA-1181a) (ng/ml)

    Time frame: Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

  11. Immunogenicity of Dato-DXd (in combination with durvalumab)

    Presence of antidrug antibodies (ADAs) for Dato-DXd (confirmatory results: positive or negative, titres).

    Time frame: Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

  12. Safety of Dato-DXd (in combination with durvalumab)

    Safety and tolerability will be evaluated in terms of AEs graded by CTCAE version 5.0

    Time frame: Randomization to final safety follow-up visit, either 90 days after last dose of study intervention for those who complete planned study intervention or 90 days after date of discontinuation for those who discontinue study intervention prematurely

07

Study locations

283 sites
  • Research Site
    Daphne, Alabama 36526, United States
  • Research Site
    Prescott, Arizona 86301, United States
  • Research Site
    Jonesboro, Arkansas 72401, United States
  • Research Site
    Rogers, Arkansas 72758, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Santa Rosa, California 92805, United States
  • Research Site
    Torrance, California 90505, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Longmont, Colorado 80504, United States
  • Research Site
    Bridgeport, Connecticut 06606, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Des Moines, Iowa 50309, United States
  • Research Site
    Edgewood, Kentucky 41017, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Baton Rouge, Louisiana 70817, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Traverse City, Michigan 49684, United States
  • Research Site
    Burnsville, Minnesota 55337, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Columbia, Missouri 65212, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    East Brunswick, New Jersey 08816, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    Santa Fe, New Mexico 87505, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Blue Ash, Ohio 45242, United States
  • Research Site
    Eugene, Oregon 97401, United States
  • Research Site
    Portland, Oregon 97223, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Dallas, Texas 75390-8843, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Flower Mound, Texas 75028, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78240, United States
  • Research Site
    Webster, Texas 77598, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Roanoke, Virginia 24014, United States
  • Research Site
    Winchester, Virginia 22601, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Feldkirch, 6807, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Antwerp, 2020, Belgium
  • Research Site
    Brasschaat, 2930, Belgium
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Libramont-Chevigny, 6800, Belgium
  • Research Site
    Brasília, 71681-603, Brazil
  • Research Site
    Curitiba, 80440-220, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90035-000, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Santo André, 09060-650, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Taubaté, 12030-200, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Shumen, 9700, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Vancouver, British Columbia VSZ 4E6, Canada
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Lévis, Quebec G6V 3Z1, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H2X 0C1, Canada
  • Research Site
    Montreal, Quebec H4A-3J1, Canada
  • Research Site
    Saint-Jérôme, Quebec J7Z 5T3, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    Ottawa, K1H 8L6, Canada
  • Research Site
    Beijing, 100044, China
  • Research Site
    Bengbu, 233004, China

Showing the first 100 of 283 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • McArthur HL, Tolaney SM, Dent R, Schmid P, Asselah J, Liu Q, Meisel JL, Niikura N, Park YH, Werutsky G, Bianchini G, Andersen JC, Kozarski R, Rokutanda N, Pistilli B, Loibl S. TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naive early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol. 2025 Feb 5;17:17588359251316176. doi: 10.1177/17588359251316176. eCollection 2025. PubMed 39917260 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2028, 60 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 60 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Nov 1, 2023
StartActual
Nov 14, 2023
Primary completionEst.
Nov 20, 2028
CompletionEst.
Sep 23, 2032
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06112379
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Nov 14, 2023
Primary completion
Nov 20, 2028 (estimated)
Completion
Sep 23, 2032 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion